This page contains a Flash digital edition of a book.
SPOTLIGHT ON


Professor Rob Storey


––– –––


Professor Storey has worked for eight years in Sheffield on new drugs for


reducing the risk of clotting in the heart blood vessels for people who have had a heart attack or a stent inserted.


He has led UK investigations of a new antiplatelet drug, ticagrelor, showing how this has a more consistent effect compared to the standard drug clopidogrel as well as a more rapidly reversible action.


He served on the executive committee of the PLATO study which has shown that ticagrelor can prevent one in five deaths in the year


following heart attack compared to clopidogrel, which is an important breakthrough for heart attack victims.


Non-mammalian models Non-mammalian systems (zebrafish) are used to model biological processes relevant to cardiovascular diseases. We have established models of collateral vessel development and macrophage behaviour.


Platelet Group The group has a major interest in development and assessment of new antiplatelet agents for use in coronary artery disease.


Pulmonary Vascular Group This group studies molecular mechanisms underlying pulmonary arterial hypertension (PAH) involving the tumour necrosis factor (TNF) superfamily e.g. osteoprotegerin (OPG, TNFRSF11B), Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL, TNFSF10) and Receptor Activator of Nuclear Factor- B Ligand (RANKL, TNFSF11).


Vascular Biology Group The overall research theme focuses on mechanisms by which leukocytes and platelets are recruited to sites of injury and inflammation in cardiovascular diseases.


Virtual Physiological Human Modelling The Department and Faculty has embarked on an exciting new venture, with the Faculty of Engineering and Sheffield Teaching Hospitals Foundation Trust to set up an institute known as Insigneo devoted to Virtual Physiological Human modelling. Supported by EU funding, the VPH develops and implements personalised computer models, based on patient data, to predict how individuals will respond to diseases and to evaluate potential treatments.


Our partnerships


International collaborations include our participation in the Zimmerman program on the molecular and clinical biology of VWD (ZPMCB-VWD), with North American collaborators in Milwaukee and Kingston, Ontario. The Platelet Group, led by Professor Robert Storey, was a major contributor to the PLATO study, published in the New England Journal of Medicine, on the effectiveness of the new drug ticagrelor at the time of heart attack. Further work will help to define the ideal treatment for patients with unstable and stable coronary disease.


25


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40